“…Patients were randomly assigned either to atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) followed by atezolizumab and bevacizumab maintenance or to cisplatin/carboplatin and pemetrexed (PC) followed by pemetrexed maintenance. 26 Median PFS was significantly improved in the ABCP group (8.48 v 5.62 months, HR, 0.62 [95% CI, 0.45 to 0.86], P = .004), without a difference in OS. Notably, the magnitude of PFS benefit with ABCP as compared with PC was more striking in certain subgroups: those with EGFR L858R (HR for PFS, 0.52 [95% CI, 0.31 to 0.88], P = .012) or brain metastases (HR, 0.32 [95% CI, 0.19 to 0.53], P < .0010).…”